Search Results - "Chong, T.W."

  • Showing 1 - 11 results of 11
Refine Results
  1. 1
    Patient-reported outcomes of neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer (NEAR) trial – a phase II trial

    Patient-reported outcomes of neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer (NEAR) trial – a phase II trial by Yang, X.Y., Aslim, E.J., Chong, T.W., Yuen, J.S.P., Tay, K.J., Ho, H.S.S., Lee, L.S.

    Published in European urology open science (Online) (01-07-2020)
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    Fecal microbiome in patients with staghorn calcium oxalate stones treated with percutaneous nephrolithotomy: A comparative study with stone-free subjects

    Fecal microbiome in patients with staghorn calcium oxalate stones treated with percutaneous nephrolithotomy: A comparative study with stone-free subjects by Lu, Y., Lim, P., Toh, K.Y., Chong, T.W.

    Published in European urology (01-03-2024)
    Get full text
    Journal Article
    Save to List
    Saved in:
  3. 3
    A0403 - Fecal microbiome in patients with staghorn calcium oxalate stones treated with percutaneous nephrolithotomy: A comparative study with stone-free subjects

    A0403 - Fecal microbiome in patients with staghorn calcium oxalate stones treated with percutaneous nephrolithotomy: A comparative study with stone-free subjects by Lu, Y., Lim, P., Toh, K.Y., Chong, T.W.

    Published in European urology (01-03-2024)
    Get full text
    Journal Article
    Save to List
    Saved in:
  4. 4
    Intense androgen receptor inhibition with neoadjuvant apalutamide does not complicate robotic prostatectomy outcomes

    Intense androgen receptor inhibition with neoadjuvant apalutamide does not complicate robotic prostatectomy outcomes by Yang, X.Y., Tiwari, R., Aslim, E.J., Tay, K.J., Yuen, J.S.P., Chong, T.W., Ho, H.S.S., Lee, L.S.

    Published in European urology (01-06-2021)
    Get full text
    Journal Article
    Save to List
    Saved in:
  5. 5
    563 Resveratrol suppresses innate immune responses following Trans-Rectal UltraSound guided (TRUS) biopsy of the prostate

    563 Resveratrol suppresses innate immune responses following Trans-Rectal UltraSound guided (TRUS) biopsy of the prostate by Chong, T.W, Goh, Y.Q, Tai, J.Y, Wong, S.C

    Get full text
    Journal Article
    Save to List
    Saved in:
  6. 6
    200 Expression of MHC molecule CD1d in renal cell carcinoma (RCC) is associated poorer cancer-specific and overall survival

    200 Expression of MHC molecule CD1d in renal cell carcinoma (RCC) is associated poorer cancer-specific and overall survival by Chong, T.W, Sim, M.Y, Huang, H.H, Lazaro, A.R, Thike, A.A, Tan, P.H

    Get full text
    Journal Article
    Save to List
    Saved in:
  7. 7
    1043 - Initial patient-reported outcomes of a phase II neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer (NEAR) trial

    1043 - Initial patient-reported outcomes of a phase II neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer (NEAR) trial by Yang, X.Y., Aslim, E.J., Chen, K., Chong, T.W., Yuen, J.S.P., Tay, K.J., Ho, H.S.S., Lee, L.S.

    Get full text
    Journal Article
    Save to List
    Saved in:
  8. 8
    Initial patient-reported outcomes of a phase II neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer (NEAR) trial

    Initial patient-reported outcomes of a phase II neoadjuvant apalutamide (ARN-509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer (NEAR) trial by Yang, X.Y., Aslim, E.J., Chen, K., Chong, T.W., Yuen, J.S.P., Tay, K.J., Ho, H.S.S., Lee, L.S.

    Get full text
    Journal Article
    Save to List
    Saved in:
  9. 9
    A nutrition support team led by general surgeons decreases inappropriate use of total parenteral nutrition on a surgical service

    A nutrition support team led by general surgeons decreases inappropriate use of total parenteral nutrition on a surgical service by Saalwachter, A R, Evans, H L, Willcutts, K F, O'Donnell, K B, Radigan, A E, McElearney, S T, Smith, R L, Chong, T W, Schirmer, B D, Pruett, T L, Sawyer, R G

    Published in The American surgeon (01-12-2004)
    “…The purpose of this study was to decrease the number of inappropriate orders for total parenteral nutrition (TPN) in surgical patients. From February 1999…”
    Get more information
    Journal Article
    Save to List
    Saved in:
  10. 10
    1037 - Neoadjuvant apalutamide (arn-509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer (NEAR) – initial results of a phase II trial

    1037 - Neoadjuvant apalutamide (arn-509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer (NEAR) – initial results of a phase II trial by Aslim, E.J., Yang, X., Ngo, N-T., Khor, L.Y., Chen, K., Chong, T.W., Yuen, J.S.P., Tay, K.J., Ho, H.S.S., Lee, L.S.

    Get full text
    Journal Article
    Save to List
    Saved in:
  11. 11
    Neoadjuvant apalutamide (arn-509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer (NEAR) – initial results of a phase II trial

    Neoadjuvant apalutamide (arn-509) and radical prostatectomy in treatment of intermediate to high risk prostate cancer (NEAR) – initial results of a phase II trial by Aslim, E.J., Yang, X., Ngo, N-T., Khor, L.Y., Chen, K., Chong, T.W., Yuen, J.S.P., Tay, K.J., Ho, H.S.S., Lee, L.S.

    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: